Hepatic steatosis in patients with nonalcoholic fatty liver disease. Nonalcoholic steatohepatitis (NASH)
Conditions
Interventions
Intervention 1: Intervention group: Both groups will receive necessary recommendations regarding dietary restrictions and increasing physical activity to at least 30 minutes daily. The Pro LDL capsule
Sponsors
Gorgan University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Presence of hepatic steatosis on ultrasound Informed consent of the patient
Exclusion criteria
Exclusion criteria: Alcohol consumption Viral hepatitis Use of certain medications such as amiodarone, anticonvulsants, and chemotherapy drugs Other chronic liver diseases Patient's refusal to start or continue the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in the severity of liver steatosis. Timepoint: 90 days after intervention. Method of measurement: Ultrasound for determining the severity of liver steatosis (mild, moderate, severe); Fibrosis-4 (FIB-4) Score, which includes 4 tests: Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), platelet count, and age. | — |
Secondary
| Measure | Time frame |
|---|---|
| Control of dyslipidemia. Timepoint: 90 days after intervention. Method of measurement: Lipid profile including: LDL, HDL, triglycerides, cholesterol.;Reduction in liver aminotransferase levels (AST-ALT). Timepoint: 90 days after intervention. Method of measurement: Measurement of serum levels of AST and ALT enzymes.;Control of hypertension. Timepoint: 90 days after intervention. Method of measurement: Blood pressure measurement.;Weight loss. Timepoint: 90 days after intervention. Method of measurement: Weighing scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarnaz Kouhsarian
Gorgan University of Medical Sciences
Outcome results
None listed